These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

725 related items for PubMed ID: 16649845

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A, Alfaro V.
    Rev Neurol; ; 42(10):607-16. PubMed ID: 16703529
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine.
    Nyakas C, Granic I, Halmy LG, Banerjee P, Luiten PG.
    Behav Brain Res; 2011 Aug 10; 221(2):594-603. PubMed ID: 20553766
    [Abstract] [Full Text] [Related]

  • 5. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN.
    J Clin Psychiatry; 2006 Aug 10; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [Abstract] [Full Text] [Related]

  • 6. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
    Song MS, Rauw G, Baker GB, Kar S.
    Eur J Neurosci; 2008 Nov 10; 28(10):1989-2002. PubMed ID: 19046381
    [Abstract] [Full Text] [Related]

  • 7. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
    Danysz W, Parsons CG.
    Int J Geriatr Psychiatry; 2003 Sep 10; 18(Suppl 1):S23-32. PubMed ID: 12973747
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL, Lladó Plarrumaní A.
    Neurologia; 2005 Dec 10; 20(10):686-91. PubMed ID: 16317590
    [Abstract] [Full Text] [Related]

  • 12. Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease.
    Motawaj M, Burban A, Davenas E, Arrang JM.
    J Pharmacol Exp Ther; 2011 Feb 10; 336(2):479-87. PubMed ID: 21057059
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
    Parsons CG, Stöffler A, Danysz W.
    Neuropharmacology; 2007 Nov 10; 53(6):699-723. PubMed ID: 17904591
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Memantine: pharmacological properties and clinical uses.
    Kumar S.
    Neurol India; 2004 Sep 10; 52(3):307-9. PubMed ID: 15472417
    [Abstract] [Full Text] [Related]

  • 18. [Therapy of Alzheimer disease].
    Kovács T.
    Neuropsychopharmacol Hung; 2009 Mar 10; 11(1):27-33. PubMed ID: 19731816
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.